Healthcare Feb 04, 2021 12:16 PM (GMT+8) · EqualOcean
EUROHEALTH, February 4 - the results of the fourth batch of national centralized procurement plans were announced yesterday. Qingdao Baiyang Pharmaceutical Co., Ltd., a subsidiary of Baiyang Pharmaceutical Group, won duloxetine hydrochloride enteric coated capsule nashu (20mg * 14 capsules) at the price of 8.25 yuan / box, a drop of nearly 85%. Depression is a common mental disease, and it is estimated that 350 million people in the world suffer from it. In China, the prevalence of depression is 2.1%. Duloxetine is mainly used in the treatment of depression and generalized anxiety disorder, especially for patients with depression accompanied by pain and other physical discomfort symptoms. In recent years, the sales growth rate of duloxetine capsules in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals has been maintained at more than 15%, and it has exceeded 600 million yuan in 2019. Zheng Aiju, general manager of Baiyang pharmaceutical, introduced that the enteric coated pellets (drug containing layer, isolation layer and enteric coated layer) of duloxetine hydrochloride enteric coated capsules selected by Baiyang pharmaceutical this time were coated with enteric coated pellets. The production process was complex, which posed a great challenge to pharmaceutical preparation technology. It is deemed to have passed the "consistency evaluation" if it obtains the US FDA marketing license in April 2019 and the drug approval certificate in China in December 2020. In addition to duloxetine, previously, Baiyang pharmaceutical's metformin hydrochloride sustained-release tablets (III) Neda and celecoxib capsule Naiqi have been approved by FDA of the United States and nmpa of China. Celecoxib capsule Naiqi has been selected in the third batch of national centralized procurement.